70 filings
Page 2 of 4
8-K
ewvkx09pcslik
15 May 23
CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides
8:36am
8-K
3cnd13adcjgqils8cwz
8 May 23
Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors
8:45am
8-K
cmbve8s5cjxyhd oha1
3 Jan 23
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors
8:45am
8-K
15jt7jwq
14 Dec 22
Other Events
4:00pm
8-K
p1yl5mdv7gqlp8
1 Dec 22
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price
5:19pm
8-K
4uepqy127bzmkamt on
28 Nov 22
CNS Pharmaceuticals Announces Reverse Stock Split
5:13pm
8-K
69tib
24 Oct 22
Other Events
5:15pm
8-K
aj6 dxhaq
26 Aug 22
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
bik8oyt9
19 Aug 22
Other Events
8:01am
8-K
n9i hrtvry
16 Aug 22
Other Events
4:02pm
8-K
umbev
15 Aug 22
CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
9:09am
8-K
nqn5vemf60b4 ku15h
4 Aug 22
Other Events
5:02pm
8-K
8g6hazz5ezk7dsv
28 Jul 22
Other Events
4:02pm
8-K
ggorm66icxqn5k
16 May 22
CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:38pm
8-K
7e39pydtgtnkuoh j8j
3 Mar 22
CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
8:40am
8-K
u2s55e5pudsqndf
18 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:04pm
8-K
47fgmc q2ld46
10 Jan 22
Regulation FD Disclosure
9:25am
8-K
nj4whwjr7t
6 Jan 22
CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
9:11am
8-K
puwacp 9cz6mb3l
3 Dec 21
Regulation FD Disclosure
4:08pm
8-K
juge0lz
13 Aug 21
CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook
8:10am